broadly neutralizing antibodies
Showing 1 - 25 of 6,122
HIV-1-infection Trial in Pathum Wan (VRC07-523LS, PGDM1400LS, N-803)
Not yet recruiting
- HIV-1-infection
- VRC07-523LS
- +7 more
-
Pathum Wan, Bangkok, Thailand
- +1 more
Mar 8, 2023
HIV Trial (Teropavimab, Zinlirvimab, Lenacapavir Tablet)
Not yet recruiting
- HIV Infections
- Teropavimab
- +4 more
- (no location specified)
Feb 6, 2023
Human Immunodeficiency Virus Trial in New York, Philadelphia (3BNC117-LS, 10-1074-LS, N803)
Not yet recruiting
- Human Immunodeficiency Virus
- 3BNC117-LS
- +2 more
-
New York, New York
- +2 more
Jul 12, 2022
HIV Infection Trial in United States (N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074)
Recruiting
- HIV Infection
- N-803 (IL-15 Superagonist)
- +2 more
-
Los Angeles, California
- +11 more
Sep 22, 2022
Broadly HIV-1 Neutralizing Antibodies in HIV-infected Mbeya,
Active, not recruiting
- HIV/AIDS
-
Mbeya, TanzaniaNIMR-Mbeya Medical Research Center (MMRC)
Aug 5, 2022
HIV-1-infection Trial in Brazil, United States (ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3)
Not yet recruiting
- HIV-1-infection
- ChAdOx1.tHIVconsv1
- +7 more
-
San Diego, California
- +11 more
Oct 4, 2023
HIV/AIDS Trial in San Francisco (Combination Intervention)
Active, not recruiting
- HIV/AIDS
- Combination Intervention
-
San Francisco, CaliforniaZuckerberg San Francisco General Hospital, University of Califor
Mar 21, 2022
HIV, HIV/AIDS, HIV-1 Infection Trial in Philadelphia (Pegylated Interferon alpha 2b (peg-IFN-a2b), 3BNC117 + 10-1074)
Unknown status
- HIV
- +2 more
- Pegylated Interferon alpha 2b (peg-IFN-α2b)
- 3BNC117 + 10-1074
-
Philadelphia, Pennsylvania
- +1 more
Jun 22, 2021
HIV, AIDS, Immunologic Deficiency Syndrome, Acquired Trial in Boston (Ad26.Mos4.HIV, MVA-BN-HIV, PGT121)
Recruiting
- HIV
- +4 more
- Ad26.Mos4.HIV
- +4 more
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Apr 18, 2022
Hiv, HIV/AIDS, HIV Trial in San Francisco, Boston, Minneapolis (N-803 and bNAbs, haNK™ Cells)
Withdrawn
- Hiv
- +5 more
- N-803 and bNAbs
- haNK™ Cells
-
San Francisco, California
- +2 more
Oct 21, 2020
HIV-1 Infection Trial in United States (Oral Lenacapavir, Subcutaneous Lenacapavir, Teropavimab)
Active, not recruiting
- HIV-1 Infection
- Oral Lenacapavir
- +3 more
-
Los Angeles, California
- +22 more
Nov 4, 2022
HIV-1-infection Trial in Worldwide (3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J)
Unknown status
- HIV-1-infection
- 3BNC117-LS-J
- +6 more
-
Boston, Massachusetts
- +8 more
Dec 11, 2020
Acute HIV Infection Trial in Brazil, Peru, United States (biological, other, drug)
Not yet recruiting
- Acute HIV Infection
- VRC07-523LS
- +3 more
-
Birmingham, Alabama
- +35 more
Jan 30, 2023
COVID-19, SARS CoV 2 Infection Trial in Orléans (Collection of biological samples)
Not yet recruiting
- COVID-19
- SARS CoV 2 Infection
- Collection of biological samples
-
Orléans, FranceCentre Hospitalier Régional d'Orléans, France
Jul 21, 2022
Hemophilia B Trial (CSL222 (AAV5-hFIXco-Padua))
Not yet recruiting
- Hemophilia B
- CSL222 (AAV5-hFIXco-Padua)
- (no location specified)
Aug 14, 2023
COVID-19; Isolation of Neutralizing Antibodies for Therapeutics
Active, not recruiting
- SARS-CoV 2
- Blood sampling
-
Grenoble, FranceUniversityGrenobleHospital
Mar 24, 2022
Coronavirus Infections Trial in Moscow (tixagevimab/cilgavimab 150+150 mg, tixagevimab/cilgavimab 300+300 mg, regdanvimab)
Active, not recruiting
- Coronavirus Infections
- tixagevimab/cilgavimab 150+150 mg
- +2 more
-
Moscow, Russian FederationMoscow City Clinical Hospital 52
Aug 7, 2023
Japanese Encephalitis, Vaccine Preventable Disease, Vaccine Reaction Trial in Lishui, Quzhou, Wenzhou (Japanese Encephalitis
Active, not recruiting
- Japanese Encephalitis
- +2 more
- Japanese Encephalitis Vaccine (Vero Cell), Inactivated;
- No prospective interventions
-
Lishui, Zhejiang, China
- +2 more
Nov 13, 2022
Treatment of BK Virus Infection in Hematopoietic Stem Cell
Recruiting
- BK Virus Infection
-
Strasbourg, FranceService Laboratoire de Virologie - PTM - CHU de Strasbourg - Fra
Nov 8, 2022
SARS-COV-2/COVID-19 Neutralizing Antibodies in Blood
Completed
- SARS-CoV2 Infection
-
Starkville, Mississippi
- +4 more
Aug 8, 2022